Cargando…
Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist
[Image: see text] Increasing human life expectancy prompts the development of novel remedies for cognitive decline: 44 million people worldwide are affected by dementia, and this number is predicted to triple by 2050. Acetylcholinesterase and N-methyl-d-aspartate receptors represent the targets of c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007108/ https://www.ncbi.nlm.nih.gov/pubmed/32401481 http://dx.doi.org/10.1021/acschemneuro.0c00244 |
_version_ | 1783672430621884416 |
---|---|
author | Ribaudo, Giovanni Ongaro, Alberto Zagotto, Giuseppe Memo, Maurizio Gianoncelli, Alessandra |
author_facet | Ribaudo, Giovanni Ongaro, Alberto Zagotto, Giuseppe Memo, Maurizio Gianoncelli, Alessandra |
author_sort | Ribaudo, Giovanni |
collection | PubMed |
description | [Image: see text] Increasing human life expectancy prompts the development of novel remedies for cognitive decline: 44 million people worldwide are affected by dementia, and this number is predicted to triple by 2050. Acetylcholinesterase and N-methyl-d-aspartate receptors represent the targets of currently available drugs for Alzheimer’s disease, which are characterized by limited efficacy. Thus, the search for therapeutic agents with alternative or combined mechanisms of action is wide open. Since variations in 3′,5′-cyclic adenosine monophosphate, 3′,5′-cyclic guanosine monophosphate, and/or nitric oxide levels interfere with downstream pathways involved in memory processes, evidence supporting the potential of phosphodiesterase (PDE) inhibitors in contrasting neurodegeneration should be critically considered. For the preparation of this Review, more than 140 scientific papers were retrieved by searching PubMed and Scopus databases. A systematic approach was adopted when overviewing the different PDE isoforms, taking into account details on brain localization, downstream molecular mechanisms, and inhibitors currently under study, according to available in vitro and in vivo data. In the context of drug repurposing, a section focusing on PDE5 was introduced. Original computational studies were performed to rationalize the emerging evidence that suggests the role of PDE5 inhibitors as multi-target agents against neurodegeneration. Moreover, since such compounds must cross the blood–brain barrier and reach inhibitory concentrations in the central nervous system to exert their therapeutic activity, physicochemical parameters were analyzed and discussed. Taken together, literature and computational data suggest that some PDE5 inhibitors, such as tadalafil, represent promising candidates. |
format | Online Article Text |
id | pubmed-8007108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-80071082021-03-30 Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist Ribaudo, Giovanni Ongaro, Alberto Zagotto, Giuseppe Memo, Maurizio Gianoncelli, Alessandra ACS Chem Neurosci [Image: see text] Increasing human life expectancy prompts the development of novel remedies for cognitive decline: 44 million people worldwide are affected by dementia, and this number is predicted to triple by 2050. Acetylcholinesterase and N-methyl-d-aspartate receptors represent the targets of currently available drugs for Alzheimer’s disease, which are characterized by limited efficacy. Thus, the search for therapeutic agents with alternative or combined mechanisms of action is wide open. Since variations in 3′,5′-cyclic adenosine monophosphate, 3′,5′-cyclic guanosine monophosphate, and/or nitric oxide levels interfere with downstream pathways involved in memory processes, evidence supporting the potential of phosphodiesterase (PDE) inhibitors in contrasting neurodegeneration should be critically considered. For the preparation of this Review, more than 140 scientific papers were retrieved by searching PubMed and Scopus databases. A systematic approach was adopted when overviewing the different PDE isoforms, taking into account details on brain localization, downstream molecular mechanisms, and inhibitors currently under study, according to available in vitro and in vivo data. In the context of drug repurposing, a section focusing on PDE5 was introduced. Original computational studies were performed to rationalize the emerging evidence that suggests the role of PDE5 inhibitors as multi-target agents against neurodegeneration. Moreover, since such compounds must cross the blood–brain barrier and reach inhibitory concentrations in the central nervous system to exert their therapeutic activity, physicochemical parameters were analyzed and discussed. Taken together, literature and computational data suggest that some PDE5 inhibitors, such as tadalafil, represent promising candidates. American Chemical Society 2020-05-13 /pmc/articles/PMC8007108/ /pubmed/32401481 http://dx.doi.org/10.1021/acschemneuro.0c00244 Text en Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Ribaudo, Giovanni Ongaro, Alberto Zagotto, Giuseppe Memo, Maurizio Gianoncelli, Alessandra Therapeutic Potential of Phosphodiesterase Inhibitors against Neurodegeneration: The Perspective of the Medicinal Chemist |
title | Therapeutic Potential of Phosphodiesterase Inhibitors
against Neurodegeneration: The Perspective of the Medicinal Chemist |
title_full | Therapeutic Potential of Phosphodiesterase Inhibitors
against Neurodegeneration: The Perspective of the Medicinal Chemist |
title_fullStr | Therapeutic Potential of Phosphodiesterase Inhibitors
against Neurodegeneration: The Perspective of the Medicinal Chemist |
title_full_unstemmed | Therapeutic Potential of Phosphodiesterase Inhibitors
against Neurodegeneration: The Perspective of the Medicinal Chemist |
title_short | Therapeutic Potential of Phosphodiesterase Inhibitors
against Neurodegeneration: The Perspective of the Medicinal Chemist |
title_sort | therapeutic potential of phosphodiesterase inhibitors
against neurodegeneration: the perspective of the medicinal chemist |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007108/ https://www.ncbi.nlm.nih.gov/pubmed/32401481 http://dx.doi.org/10.1021/acschemneuro.0c00244 |
work_keys_str_mv | AT ribaudogiovanni therapeuticpotentialofphosphodiesteraseinhibitorsagainstneurodegenerationtheperspectiveofthemedicinalchemist AT ongaroalberto therapeuticpotentialofphosphodiesteraseinhibitorsagainstneurodegenerationtheperspectiveofthemedicinalchemist AT zagottogiuseppe therapeuticpotentialofphosphodiesteraseinhibitorsagainstneurodegenerationtheperspectiveofthemedicinalchemist AT memomaurizio therapeuticpotentialofphosphodiesteraseinhibitorsagainstneurodegenerationtheperspectiveofthemedicinalchemist AT gianoncellialessandra therapeuticpotentialofphosphodiesteraseinhibitorsagainstneurodegenerationtheperspectiveofthemedicinalchemist |